We describe a heterologous, Semliki Forest virus (SFV)-driven packaging system for the production of infectious recombinant Moloney murine leukemia virus particles. The gag-pol and env genes, as well as a recombinant retrovirus genome (LTR-q+sneoR-LTR), were inserted into individual SFV1 expression plasmids. Replication-competent RNAs were transcribed in vitro and introduced into the cytoplasm of BHK-21 cells using electroporation. The expressed Moloney murine leukemia virus structural proteins produced extracellular virus-like particles. In these particles the gag precursor was processed into mature products, indicating that the particles contained an active protease. The protease of the gag-pol fusion protein was also shown to be active in a trans-complementation assay using a large excess of Pr65gag. Moreover, the particles possessed reverse transcriptase (RT) activity as measured in an in vitro assay. Cotransfection of BHK-21 cells by all three SFV1 constructs resulted in the production of transduction-competent particles at 4 x 106 colony-forming units (cfu)/ml during a 5-hr incubation period. Altogether, 2.9 x 107 transductioncompetent particles were obtained from about 4 x 106 transfected cells. Thus, this system represents the first RNA-based packaging system for the production of infectious retroviral particles. The facts that no helper virus could be detected in the virus stocks and that particles carrying the amphotropic envelope could be produced with similar efficiency as those that carry the ecotropic envelope make the system very interesting for gene therapy.
Retroviruses are positive, single-stranded RNA viruses that replicate via a chromosomally integrated DNA intermediate (provirus) (1, 2) . After entering into a new cell, viral RNA is transcribed into double-stranded DNA using a virus-specific RT (3) . The viral genome is transported into the nucleus, where it is integrated into the host DNA with the aid of a second virus-specific enzyme, the integrase (4). Expression of viral genes is initiated by transcription of provirus into RNA. The latter is transported from the nucleus into the cytoplasm, where it is either used for packaging into progeny particles, or as mRNA for translation of viral gag, gag-pol, and env precursor proteins. gag and gag-pol precursors are translated from full-length RNA, whereas the env precursor is made from a subgenomic RNA, which is derived from the longer form by RNA splicing. Translation of full-length RNA yields mostly gag precursor proteins. However, gag-pol fusion products are also synthesized, either because of suppression of the gag stop codon (5) or because of ribosomal frameshifting (6) (7) (8) . Thepol gene encodes a third enzyme, an aspartyl protease (PR), which is responsible for almost all of the maturation cleavages of the viral precursor proteins (9) .
Because of their characteristic life-cycle, retroviruses are widely used as vectors for stable expression of heterologous genes in mammalian cells. These systems have also been adapted for the purpose of gene therapy in humans (10, 11) . One of the most important innovations was the successful construction of helper cell lines that synthesize all retroviral proteins, but which do not produce infectious particles because they lack a transduction-competent genome (12) . Transfection of these cells by recombinant proviral DNA that encodes the RNA-encapsidation signal results in production of particles carrying the recombinant genome. These particles are infectious, but of the so-called suicide type; that is, they cannot spread because they do not express structural proteins of the virus. This feature is essential especially if the particles are to be used in human gene therapy.
The best characterized packaging systems today are those derived from Moloney murine leukemia virus (MoMuLV) (13) . Although preliminary experiments have shown that it is feasible to use recombinant particles produced by these systems for gene therapy, further improvement is required. Ideally, the production system should be fast and easy to use and yield a high titer stock of transduction competent particles, which is devoid of any replication proficient helper viruses. In addition, its flexibility is important; for instance, it should be possible to choose freely among surface protein genes that code for envelope proteins with different targeting specificity. These considerations have aroused interest to produce recombinant retroviruses by transient expression systems rather than by the standard packaging cell lines (14, 15) . We and others have recently developed expression systems based on the alphaviruses (Semliki Forest and Sindbis virus; refs. 16 and 17) . These systems monopolize on the ability of the alphavirus RNA genome to self-replicate very efficiently in the cell cytoplasm. The major advantages of alphavirus systems, as compared with other expression systems, are their ease of use, and the high levels of RNA and protein produced in transfected cells. Therefore, we were interested in determining if the Semliki Forest virus (SFV) system could be used to reconstitute assembly of infectious MoMuLV particles.
Plasmid Constructs. The essential features of the SFVbased constructs used in this work are shown in Fig. 1 .
pSFV1/Pr8Oenv andpSFV-C/Pr65gag. pSFV1/Pr8oenv and pSFV-C/Pr65gag have been described (18) . pSFV1/Pr8oenv contains a DNA copy of the MoMuLV Pr80env gene under the control of the SFV subgenomic promoter. In pSFV-C/Pr65gag the coding sequence of MoMuLV Pr65gag is fused to the capsid (C) gene of SFV. RNA transcribed from the latter plasmid can be used for high level expression of Pr65gag, due to a translational enhancer present in the SFV C gene (19) . In SFV-C/Pr65gag RNA-transfected cells, a C-gag fusion protein is initially produced. SFV C posesses autoproteolytic activity and therefore cotranslationally cleaves itself off from the nascent chain giving C and free Pr65gag. The latter is further processed by myristoylation.
pSFVJ/gag-pol and pSFV-C/gag-pol. pSFV1/gag-pol was made by inserting the MoMuLV gag-pol cDNA from pNCA (20) into the BamHI site of pSFV1 via subcloning steps in pGEM-7Zf(+) (Promega) and M13mpl8 (GIBCO/BRL). The two SpeI sites in the gag-pol cDNA were removed by site-directed mutagenesis, using the oligonucleotide 5'-GGGG-GGTTGTTTGACGAGTGCCTCTACTGCATGGGGGGCC-AGAATGACGAGTGGCTGTCCCATGGT-3' (21). pSFV-C/ gag-pol was made by ligating the NotI-BsmI fragment (14,410 bp) of pSFV1/gag-pol and the NotI-BsmI fragment (2,723 bp) of pSFV-C/Pr65gag. In pSFV-C/Pr65gag and pSFV-C/ gag-pol the regions encoding the MoMuLV proteins are fused to that of SFV capsid (C) gene. pSFV1/LN3i contains the 5' R-U5, the encapsidation signal (i++), the neoR gene, and the 3' U3-R sequences from the retrovirus vector pLN, and 38 SFV-specific bases (denoted with *) both before the R region at the 5' end and between the 3' U3 and R region. The SFV recombinant region is transcribed into RNA using SP6 RNA polymerase following linearization of the DNA with SpeI or NruI depending on the construct. The SFV polymerase complex both replicates the RNA and transcribes the 3' portion from the internal subgenomic promoter into a subgenomic mRNA from which the env precursor protein (SFV1/Pr80env and SFV1/AMenv), the SFV-C-gag fusion protein (SFV-C/Pr65gag), the gag-pol precursor protein (SFV1/gag-pol), or the SFV-C-gag-pol fusion protein (SFV-C/gag-pol) is translated. Note that coding regions indicated are not to scale. pSFVl/LN3i. pSFV1/LN3i was made by inserting a recombinant MoMuLV gene (R-U5-+-neoR-U3-R) from pLN (22) into the SmaI site of pSFV1-NruI plasmid vector. pSFV1-NruI is a derivative of pSFV1, made by deleting a 527-bp StuIHindIII fragment (7603-8130) from pSFV1 and changing the unique Spel site to an NruI site. This plasmid was a kind gift from Peter Liljestrom (Karolinska Institute). The recombinant retroviral genome in pSFV1/LN3i is flanked at the 5' end by 38 SFV-specific bases (part of which encodes the internal SFV promoter). According to the model for retroviral DNA synthesis by RT, a strong-stop DNA is synthesized near the 5' end of the retrovirus RNA genome (23) . This strong-stop DNA then jumps to the 3' end, and the exposed R sequence hybridizes with the complementary R sequence at the 3' end of the retrovirus RNA genome for synthesizing the minusstrand DNA. The 38 SFV specific bases inserted in front of the 5' end R region would interrupt the minus-strand DNA synthesis. To facilitate the conversion of the RNA into doublestranded DNA, we also inserted the same 38-base long SFV sequence between the 3' U3 and R regions. This was done by fusion-PCR (24) using Vent DNA polymerase (New England Biolabs) and a subcloning step in pUC18.
pSFVl/AMenv. Plasmid pSFV1/AMenv contains the coding sequence of the murine amphotropic virus (4070A) envelope protein. The amphotropic envelope gene fragment from pPAM3 (25) was first inserted into pUC18 by subcloning steps to make pUC18/AMenv. The plasmid pSFV1/AMenv was made by inserting the SmaI-HpaI fragment (1976 bp) from pUC18/AMenv into the SmaI site of pSFV1-NruI.
RNA Transcription and Transfection. Run-off transcripts were produced in vitro from Spel-linearized pSFV-C/Pr65gag, pSFV1/gag-pol, pSFV-C/gag-pol, pSFV1 /Pr80env, NruIlinearized pSFV1/LN3i, pSFV1/AMenv using SP6 RNA polymerase (26) . RNA (20 ,lI of each) was transfected into 8 x 106 BHK-21 cells by electroporation. Fifty to 75% of the cells survived the transfection step.
Metabolic Labeling of Transfected Cells. Transfected cells were added to 9 ml of complete BHK-21 medium, plated onto three 33-mm culture dishes, and incubated at 37°C. At 8 hr after electroporation, transfected cells were washed twice with phosphate-buffered saline (PBS) and starved by incubation at 37°C for 30 min in 2 ml of methionine-free minimum essential medium (MEM; GIBCO), supplemented with 20 mM Hepes. Media were then replaced with 0.5 ml of methionine-free MEM containing 100 ,uCi (1 Ci = .376Bq) of [35S]methionine per ml. After a 30-min pulse, cells were washed twice with MEM containing 20 mM Hepes and 150 ,tg/ml of unlabeled methionine (chase medium). Incubation was then continued in chase medium for different times. At the end of each chase period, culture media were collected, cell monolayers were washed once with PBS and then solubilized in 0.3 ml of lysis buffer [1% sodium dodecyl sulfate (SDS)/10 mM iodoacetamide]. Media samples and cell lysates were clarified by centrifugation using an Eppendorf centrifuge, at 6000 rpm, for 6 min.
Protein Analysis. Cell lysates (0.3 ml) were diluted to 3 ml with NET buffer (150 mM NaCl/1 mM EDTA/50 mM Tris-HCl, pH 7.5/0.1% Nonidet P-40/0.25% gelatine/0.02% sodium azide). To immunoprecipitate MoMuLV-specific proteins, S ,ul of polyclonal pig anti-MoMuLV antiserum (HC 185, Quality Biotech, Camden, NJ) and 40 ,ll of protein ASepharose (Pharmacia) slurry [1:1 (vol/vol) in 10 mM Tris.HCl] were added to 1 ml of diluted cell lysate, and samples were incubated overnight at 4°C. Immunoprecipitates were washed as described (27) and analyzed by SDS/12% PAGE under reducing conditions. Extracellular particles in media samples were pelleted through a 20% sucrose cushion at 17,000 rpm, for 2 hr, at 10°C, using a Beckman JA18.1 rotor. Pellets were analyzed by SDS/PAGE as described above. Gels were dried and exposed to Fuji film. Dried gels were also exposed Film) , and the amount of radioactivity in bands was quantitated using the Fuji BioImage analyzer system BAS2000 (Fuji Photo Film).
RT Assay. This was done essentially as described in ref. 28 . Briefly, a 10-,ul aliquot of each medium sample was added to a 50-,ul aliquot of a reaction cocktail, giving a final reaction mixture containing 50 mM Tris'HCl (pH 8.3), 20 mM DTT, 0.6 mM MnCl2, 60 mM NaCl, 0.05% Nonidet P-40, 1 ,ug of poly(rA)p(dT)12_18 (Pharmacia), and 10 ,uCi of [a-32P]dTTP (Amersham). After incubation at 37°C for 1 hr, 10 ,lI of each sample was spotted onto sheets of dry Hybond-N+ nucleic acid transfer membrane (Amersham). Membranes were washed at room temperature with gentle agitation, 3 x 20 min in 500 ml of 0.3 M NaCl/0.03 M sodium citrate and twice briefly in 500 ml of 95% ethanol. After air-drying, membranes were exposed to a BAS-II Image Plate and radioactivity was quantitated as above.
RNA Analysis. Transfected BHK-21 cells were plated onto 33-mm culture dishes and incubated for 2 hr at 37°C. Media were removed and replaced with 1-ml aliquots of medium containing 1 ,tg/ml actinomycin D (Sigma/Aldrich). After incubation for 2 hr at 37°C, media were replaced with 1-ml aliquots of medium containing 1 jig/ml actinomycin D and 75 KBq [14C]uridine (2.1 GBq/mmol, DuPont). After incubation for 6 hr at 37°C, cellular RNA was isolated using TRIzol Reagent (GIBCO) as described by the manufacturer. RNA was dissolved in RNase-free H2O and subjected to electrophoresis through 0.7% agarose gels containing formaldehyde (29) . Gels were dried, and radiolabeled RNA was visualized by autoradiography.
Production of Infectious Recombinant Retrovirus Particles.
BHK-21 cells were transfected by electroporation with SFV1/ LN3i, SFV1/Pr80env (or SFV1/AMenv), and SFV1/gag-pol (or SFV-C/gag-pol) RNAs. The transfected BHK-21 cells were diluted into 9 ml of complete BHK medium, and 6 ml of the cell suspension (containing 3-4 x 106 living cells) was plated onto a 60-mm culture dish (Nunclon, Naperville, IL). The cells were incubated at 37°C, and the media were harvested at 5-hr intervals from the same dish and replaced with 2-ml aliquots of fresh complete BHK medium. Fig. 24 (lanes 1-5) show MoMuLV proteins that were immunoprecipitated from cell lysates: Pr65gag and one of its cleavage products, the viral capsid protein p30, are clearly visible. Fig. 2A (lanes 6-10) show the proteins of the released gag-pol particles: These particles contained the Pr65gag cleavage products, p30 and ppl2. Two additional gag products, p15 (matrix protein) and plO (nucleocapsid protein), are not visible because they lack methionines. Therefore SFV1/gag-pol RNA expressed functional viral PR, because the particles contained fully processed structural proteins.
PR Expressed from SFV1/gag-pol RNA Cleaves Pr65gag Expressed from a Separate Replicon. To further check that PR functioned correctly, we tested its ability to cleave Pr65gag expressed from a separate replicon. SFV1/gag-pol RNA and SFV-C/Pr65gag RNA, the latter from which proteins are expressed at about a 10-fold higher level, were cotransfected into BHK-21 cells. Cells were pulse-labeled and chased, and cell-associated and extracellular MoMuLV proteins were analyzed by SDS/PAGE. Fig. 2B shows expression of uncleaved Pr65gag in cells transfected with SFV-C/Pr65gag RNA alone:
As expected, about 10-fold more of Pr65gag was obtained in comparison with the SFV1/gag-pol RNA transfected cells ( Fig. 2A) . Fig. 2B (lanes 1-5) shows uncleaved intracellular Pr65gag, the amount of which decreased with time as gag particles were released from cells (Fig. 2B, lanes 6-10) . Fig. 2C shows SDS/PAGE analysis of cell-associated and extracellular virus-specific proteins from cells cotransfected with SFV-C/ Pr65gag and SFV1/gag-pol RNAs at the ratio of 1:1. Most of the Pr65gag expressed from SFV-C/Pr65gag RNA was processed to p30 and ppl2. Efficiency of cleavage was increased when SFV-C/Pr65gag and SFV1/gag-pol RNAs were transfected at a ratio of 1:2 (data not shown). We conclude that PR expressed from SFV1/gag-pol RNA functioned efficiently. RNA was made and transfected into cells. The synthesis of genomic and subgenomic SFV RNAs was followed by labeling with
[14C]uridine in the presence of actinomycin D, as described in Materials and Methods. As shown in Fig. 4 (lane 1) , high levels of both SFV1/LN3i genomic and subgenomic RNAs were transcribed.
Next we investigated whether the recombinant retrovirus RNA genome that was transcribed in the cytoplasm would be encapsidated to form infectious recombinant particles. For this purpose, BHK-21 cells were cotransfected with the SFV1/ gag-pol, SFV1/Pr80env, and SFV1/LN3i RNAs. The RNA analyzes are shown in Fig. 4 (lane 4) . This shows that the genomic and subgenomic RNAs of SFV1/gag-pol, SFV1/ Pr80env, and SFV1/LN3i were all produced in the cotransfected cells. The particle production was followed in a time course experiment. Cotransfected cells were incubated for a total of 25 hr. At 5-hr intervals, the medium was collected and replaced by fresh one. The presence of infectious recombinant particles in the media was tested by the ability to transduce the neoR gene into NIH 3T3 cells. This was assayed by the selection of G418-resistant colonies. The results are shown in Table 1 . During the first 5-hr incubation, 3.7 x 104 infectious particles were produced per milliliter; this increased to 6.5 x 105-1.1 X 106 transduction-competent particles per milliliter during the subsequent intervals.
To increase the production of infectious particles, we made the pSFV-C/gag-pol construct. This encodes the translation enhancing RNA sequence of the SFV capsid gene in front of the gag-pol gene (Fig. 1) . The expression of gag-pol products in cells transfected with SFV-C/gag-pol RNA is shown in Fig.   5 . This is much higher than that of the corresponding products in SFV1/gag-pol RNA transfected cells. Quantitation of radioactivity in bands shows that the difference is about 5-fold.
When the SFV-C/gag-pol RNA was used in a cotransfection/ time course experiment we found that the production of infectious particles was considerably increased ( Table 1 ). The titer in most 5-hr media samples was about 4 x 106 cfu/ml. Control experiments showed that no transduction-competent particles were released into media of cells transfected with SFV1/LN3i and SFV-C/gag-pol, SFV1/LN3i and SFV1/ Pr80env or SFV1/LN3i and SFV1/AMenv RNAs, respectively. We conclude that a retrovirus genome, which has been produced in the cell cytoplasm using the SFV expression system, can be encapsidated by coexpressed packaging proteins into a high titer stock of transduction-competent recombinant retrovirus.
Multiplication-Proficient Particles Were Not Detected. The possible presence of multiplication-proficient particles in culture media containing 2.6 x 106 infectious recombinant particles was tested by addition of media samples to No colonies were obtained for media from 3T3ZipneoSV(X)p cells infected with either the recombinant particles produced by the SFV expression system or the negative-control media. In contrast, about 4000 colonies were obtained using the positive-control media containing wild-type retrovirus.
Production of Particles with Amphotropic Envelope. The infectious recombinant retrovirus particles described above contain the ecotropic envelope glycoprotein. This can only target the virion to rodent cells. To broaden the host range of target cells for the particles and to make the system suitable also for human cells, for instance in the context of gene therapy, we set up experiments for the production of MoMuLV particles, which were pseudotyped with the amphotropic envelope glycoprotein. First we constructed an SFV1 based expression plasmid for the amphotropic envelope protein (pSFV1/AMenv in Fig. 1 ), which could be used for the in vitro transcription of corresponding RNA. This was used in a cotransfection experiment with SFV1/LN3i and SFV-C/gagpol RNAs for particle production. As can be seen in Table 1 Potentially, replication competent helper virus can be generated in our system through recombination (31) . However, this would require three separate recombination events: one between the 5' end of the recombinant neoR_containing genome and the 5' end of the gag-pol genome, a second between the 3' end of gag-pol and the 5' end of the env genome, and a third between the 3' end of env and the 3' end of the recombinant neoR-encoding genome. Since, in addition, homologous regions between different constructs are minimal, we think it is very unlikely that such recombination events would occur. Indeed, we could not detect any multiplicationproficient retrovirus in our recombinant stock. It should also be noted that our system cannot produce any multiplicationcompetent SFV-like particles because the genes encoding SFV structural proteins are not included in this system. Thus, the SFV-based recombinant retrovirus production system appears to be both efficient and helper free. Proc. Natl. Acad. Sci. USA 93 (1996) Proc. Natl. Acad. Sci. USA 93 (1996) 11663
The fact that we were able to produce recombinant particles with the amphotropic envelope at high titers makes the SFV system very interesting for the purpose of human gene therapy. The major advantage with this system is that it is convenient to use: once the required recombinant plasmids have been constructed, a recombinant retrovirus stock can be prepared within 1 day. For comparison, it takes a few months to establish a good producer cell line for a certain recombinant retrovirus. The present system is also very versatile. For instance, the targeting of the recombinant particles can easily be changed by using another envelope protein (or membrane protein) specifying RNA construct in the cotransfection. Finally, this system appears very useful for the production of recombinant retroviruses which carry a gene for a toxic product. Such recombinant particles can only be made by transient production systems which avoid the culturing of the producer cells for long time periods. In this system the packaging time is limited to about 1 day.
Landau and Littman (14) have reported another transient expression system in which simian virus 40-derived DNA vectors were used to drive the production of MoMuLV particles in COS-7 cells. During a 72-hr incubation period they obtained titers of 2.3 x 104 transduction-competent particles per milliliter from cells cotransfected with three expression plasmids, which encoded the gag-pol precursor, the env precursor, and a recombinant genome respectively. This should be compared with the titer of 2 x 106 cfu/ml that we obtained in BHK 21 cells after cotransfection with the corresponding SFV RNA constructs. When using a two plasmid system, i.e., a gag-pol env and a recombinant genome construction, Landau and Littman obtained a titer of 1.3 x 105 and 0.9 x 105 cfu/ml for ecotropic and amphotropic virus, respectively. More recently, Pear and coworkers (15) have described another transient DNA transfection system for production of recombinant retrovirus particles. They used the highly transfectable Ad5 transformed embryonic kidney cell line 293 for the generation of a packaging cell line BOSC 23 containing separate expression units for the MoMuLV gag-pol and env precursor proteins. When transfected transiently with a neoR gene containing recombinant retrovirus DNA, Pear and coworkers obtained helper free virus stocks containing 3.9 x 106 transduction-competent particles per milliliter. This is similar to the virus titer we obtained. However, our system is more useful when manipulations of the retrovirus packaging genes are desired.
The SFV based recombinant retrovirus production system reported in this work represents a novel approach. We foresee several modifications of the system that are likely to increase its production efficiency. Altogether, we think that it represents a useful system for the production of transductioncompetent retrovirus particles and that it has the potential to become important for the purpose of gene therapy in future.
